GenTegra®  Nucleic Acid Stabilization

GenTegra® news and events.


Tasso and GenTegra® LLC simplify blood draws, awarded $3M expansion.

Texas A&M AgriLife Research and GenTegra® LLC are awarded contract continuation.

GenTegra LLC, launches new RNA ambient stabilization product.


Tasso and GenTegra simplify blood draws, awarded $3M expansion.

Madison, Wis., and Pleasanton Ca., April 7, 2015 -- Tasso, Inc., a medtech start-up developing the HemoLink™, a small disposable device to simplify blood sampling, has secured an additional $2.9M in grant funding to advance its HemoLink technology with its development partner GenTegra LLC.

Based on progress made in developing the HemoLink, the Defense Advanced Research Projects Agency (DARPA) has expanded Tasso's ongoing Phase II SBIR contract. Tasso and GenTegra are developing an integrated device that is able to collect blood from patients and stabilize biomarkers at ambient temperatures without requiring cold chain transportation. The stabilization component of the grant is a $1.3M allocation to GenTegra LLC, whose Matrix Chaperone™ technology is redefining the boundaries of ambient sample stabilization.

Dr. Erwin Berthier, VP of Tasso and principal investigator on the contract, emphasized, "This is a disruptive technology that will enable connecting anyone in the world - from home, rural areas, low resource locations, or war zones - to a centralized blood analysis laboratory, providing affordable cutting edge diagnostics to everyone."

The HemoLink device safely collects blood from the surface of the skin, effectively replacing the need for venipuncture across a broad number of diagnostic tests.  The Matrix Chaperone stabilizes biospecimens at a broad range of ambient temperatures in order to preserve the vast diagnostic data offered by a blood sample. This combination of disruptive technologies fundamentally changes the way blood testing is done, replacing hospital-centric testing with testing focused on the user. Tasso President, Ben Moga states, "Together, this powerful HemoLink-Matrix Chaperone combination will modernize the diagnostic process by providing superior and affordable 'in home' and 'point of care' access to healthcare."

Bruce Jamieson, CEO of GenTegra, offers, "GenTegra is pleased to be working with the innovative HemoLink device that Tasso is developing as an alternative to venipuncture blood collection. As a part of the HemoLink device our stabilization chemistry, Matrix Chaperone, stabilizes the blood in dry form for convenient shipping and any queue time at the clinical lab while waiting for diagnostic testing. The temperature range that is protected coincides with commercial carriers' specifications, enabling the shipment of specimens in a simple mailer - free from cold chain requirements. The combination of a simple blood collection device and stabilization of the specimen at ambient temperatures will open many possibilities for new innovative 'in home' and 'point-of-care' sample collection scenarios."

GenTegra LLC has redefined ambient temperature stabilization of nucleic acids and other biomolecules through proprietary chemistries that protect and preserve in a biological matrix or as purified. In liquid form, the products protect specimens while being processed and when dried specimens are protected for years.

Contact:
James Nelson, VP Marketing & Sales
jamesn@gentegra.com
phone: 925-461-3010 www.GenTegra.com

(top)

Texas A&M AgriLife Research and GenTegra LLC are awarded contract continuation.

Ambient Temperature Biospecimen Collection, Transport & Banking For Simplified Animal Disease Screening

Pleasanton, Calif.—The National Center for Foreign Animal and Zoonotic Disease Defense (FAZD Center) and GenTegra LLC today announced the awarding of a joint collaboration to continue work on the “Matrix Chaperone” sample collection device. The FAZD Center is a U.S. Department of Homeland Security (DHS) Science and Technology Center of Excellence and is led by Texas A&M AgriLife Research, an agency of The Texas A&M University System.

Texas A&M University System Chancellor, John Sharp, endorsed this effort, "Our ultimate goal here is to advance research toward new and better solutions, improving people's lives. This collaboration with GenTegra is a great example of how higher education and industry can develop life-changing technology."

The overall goal of this project is to develop and validate a new technology to enhance the collection, preservation, and shipping of disease outbreak samples to the diagnostic laboratory. The project applies a novel dry-state ambient temperature technology (Matrix Chaperone), developed at GenTegra towards enhancing sample preservation to allow for more robust down stream testing. The initial proof-of-concept study focused on utilizing the technology with avian samples in both a laboratory and field setting. Funded by the DHS Science and Technology Directorate’s Chemical and Biological Defense Division, the expansion of this proof-of-concept study will involve evaluation of this technology under field conditions, with both swabs and serum from avian sources.

The Matrix Chaperone technology would eliminate the need for cold-chain storage (refrigerated or frozen), both simplifying the process and enhancing sample preservation during the movement of samples from the field to the laboratory. This technology has broad applications both in the U.S. and globally.

GenTegra has completed pilot scale manufacturing of a series of customized swabs, and bench testing and field sampling are underway. In response to feedback from researchers at the FAZD Center, GenTegra developed multiple sizes of the swab to enable sampling of birds and livestock, and have begun sampling in the field.

The FAZD Center performs research and develops products to defend the nation from high-consequence foreign animal, emerging and zoonotic diseases. Founded in April 2004 as a DHS Science and Technology Center of Excellence, the FAZD Center works with investigators, end users and stakeholders to develop products that meet identified national priorities and help protect the agricultural critical infrastructure and the economy. The Center has robust programs in disease discovery, information technology, knowledge products, education and training curriculum, policy development, and technology commercializati.

GenTegra-RNA dry Bulk is in stock and ready for immediate shipment

Contact:
Melissa Berquist, Ph.D
Associate Director
mlberquist@ag.tamu.edu
phone: 979.845.2855

GenTegra LLC has redefined ambient temperature stabilization of nucleic acids and other biomolecules through proprietary chemistries that protect and preserve in a biological matrix or as purified. In liquid form, the products protect specimens while being processed and when dried specimens are protected for years.

Contact:
James Nelson, VP Marketing & Sales
jamesn@gentegra.com
phone: 925-461-3010 www.GenTegra.com

(top)


Protect your RNA samples immediately, and for all its tomorrows

GenTegra LLC, launches new RNA ambient stabilization product.

GenTegra LLC, Pleasanton, CA, announces launch of GenTegra®-RNA dry Bulk.

GenTegra-RNA is groundbreaking technology for the stabilization, transport and storage of purified RNA. GenTegra is a water-soluble, inert chemical matrix that inactivates trace RNase in the liquid phase, providing an added level of RNA stability during sample handling, with or without using an ice bucket. In the dry-state, GenTegra-RNA imparts thermal stability at temperatures ranging from -80°C to 76°C and ensures quantitative recovery of RNA upon rehydration.

With the addition of GenTegra-RNA dry BULK to its line of products GenTegra LLC now offers a product that is ideally suited for automated processing of RNA samples. Mike Hogan, GenTegra's CSO stated, "I am proud that the dry bulk form of GenTegra-RNA allows us to offer its protection to applications that were not previously feasible. Researchers now have GenTegra-RNA in a form that is ideal for stabilizing RNA samples during automated processing." As delivered, the product has an unlimited shelf life and is ready for use by simply adding water.

Using GenTegra-RNA early in the RNA purification process provides protection at the earliest possible moment to ensure the highest possible yield of RNA. The protection extends to virtually all forms of RNA. After sample processing the RNA solution can be dried for permanent safe ambient storage of the sample until needed.

GenTegra-RNA is ideal for protecting RNA samples that need shipping from one research lab to another. Protection from GenTegra-RNA spans the complete range of temperatures defined by both FedEx shipping and for military uses. Full protection is provided in the range of -80°C to +56°C for up to 7 months. When stored at ambient temperatures the samples are completely stable for years.

GenTegra-RNA also protects through multiple rehydration and re-drying cycles allowing up to four aliquots to be taken from the sample over time.

GenTegra-RNA dry Bulk is in stock and ready for immediate shipment

Contact:
James Nelson, VP Marketing & Sales
jamesn@gentegra.com
phone: 925-461-3010 www.GenTegra.com

(top)